The Tata Institute in Mumbai, renowned for its cancer research and treatment, has made a groundbreaking announcement regarding a new treatment method that could revolutionize cancer therapy. After a decade of dedicated research, doctors at the institute have developed a tablet that they assert can prevent the recurrence of cancer in patients, significantly reducing the side effects of conventional treatments like radiation and chemotherapy.
The research, led by Dr. Rajendra Badve, a senior cancer surgeon at Tata Memorial Hospital, focused on understanding the behavior of cancer cells post-treatment. They discovered that dying cancer cells release cell-free chromatin particles (cfChPs), which have the potential to turn healthy cells into cancerous ones. To combat this, the researchers developed a tablet containing pro-oxidant ingredients like resveratrol and copper (R+Cu), which generate oxygen radicals capable of destroying these harmful chromatin particles.
According to Dr. Badve, the ‘R+Cu’ tablet, when ingested orally, produces oxygen radicals in the stomach, which are rapidly absorbed into the bloodstream. These radicals effectively neutralize the cfChPs circulating in the body, thereby preventing the spread of cancer cells to other parts of the body, a process known as metastasis. Moreover, the tablet is said to alleviate the toxicity associated with chemotherapy, offering relief to cancer patients undergoing treatment.
The researchers tout this breakthrough as the “Magic of R+Cu,” highlighting its potential to transform cancer therapy by minimizing treatment side effects and preventing cancer recurrence. The tablet has shown promising results in reducing side effects by up to 50%, and its efficacy in preventing cancer recurrence is estimated to be around 30%.
While awaiting approval from the Food Safety and Standards Authority of India (FSSAI), the tablet is anticipated to hit the market by June-July. Dr. Badve emphasizes its affordability, stating that unlike traditional cancer treatments costing lakhs to crores, this tablet will be accessible to all at just Rs 100.
Despite initial skepticism and challenges faced during the research, the success of this innovative treatment approach marks a significant milestone in cancer treatment. While human trials are ongoing, the potential of this tablet to improve cancer care and make it more accessible offers hope to millions battling this debilitating disease.
Sources By Agencies